Two patient groups subjected to overtreatment are those with ductal carcinoma in situ (DCIS) and those with estrogen receptor-positive (ER+) breast cancer (BC) [3, 4]. This evidence concerns the gene ESR1 and ductal breast carcinoma in situ.